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ABSTRACT
Mutations in CYP21 (21-hydroxylase) lead
to congenital adrenal hyperplasia (CAH). We
genotyped 26 probands with CAH by PCR-
sequencing the entire CYP21 gene. 25/26 had
homozygous or compound heterozygous muta-
tions. The frequencies of mutations were similar
to other populations with deletion/hybrid, 12 G
splice and I172N the most common. Five
patients with a 1172N allele predicting simple-
virilising CAH had a salt-wasting phenotype.
Two other probands also had a more severe
phenotype than predicted by genotype. Two
families had both non-classic and salt-wasting
phenofypes arising from combinations of three
deleterious alleles. Two novel CYP21 alleles were
detected: D106N and a large deletion encom-
passing CYP21 and adjacent pseudogene. Two
rare CYP21 alleles were also found. Three of
these four novel/rare alleles were only detected
as a result of sequencing the entire CYP21 gene.
Entire CYP21 sequencing will increase the
number of mutations detected in CAH, and in
combination with functional studies should
contribute a greater understanding of pheno-
type-gcnotype correlations.
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INTRODUCTION
Congenital adrenal hyperplasia (CAH) caused
by 21-hydroxylase deficiency is one of the most
common autosomal recessive disorders in man. 21-
Hydroxylase is encoded by CYP2I, and the
estimated carrier frequency of deleterious CYP2I
mutations is one in SO1'2. The CAH phenotype
reflects the degree of 21-hydroxylase enzyme
deficiency2. Complete enzyme deficiency with
combined impairment of cortisol and aldosterone
synthesis results in the classic salt-wasting (SW)
form which is characterised by prenatal virilisation
in females secondary to excess fetal androgen
exposure and salt-wasting crises in the neonatal
period. Partial enzyme deficiency leads to classic
simple virilising (SV) CAH, which is characterized
only by prenatal virilisation in females and pseudo-
precocious puberty in males and females. Data
from neonatal 17-hydroxyprogesterone (17OHP)
screening of ~6.5 million newborn infants from
USA, France, Italy, New Zealand, Japan, UK.
Brazil, Switzerland, Sweden, Germany, Portugal,
Canada, and Spain show an incidence of 1/15.000
live births for classic SW/SV CAH34. The non-
classic (NC) form of CAH is associated with a
milder degree of enzyme impairment, and is
associated with pseudoprecocious puberty, hirsu-
tism, acne, and/or subfertility2. The prevalence of
NC CAH in the white population is estimated at
-1/1,OOO5·6.
Although the different clinical subgroups of
CAH appear well defined there is in reality a
spectrum of phenotypic severity ranging form
carriers through to those with classic salt, wasting.
Males without evidence of salt wasting may be
* Y.W.A. Jeske and I.N. McGown contributed equally to this
study.
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difficult to assign to either the simple virilising or
the non-classic group. Likewise, a female without
salt wasting can only be assigned to either the
simple virilising or the non-classic group if the
appearance of the external genitalia has been
carefully documented at birth.
The 21-hydroxylase gene CYP21 (CYP21A2,
CYP21B, OMIM#201910) is located on chromo-
some 6p21.3 within the HLA histocompatibility
complex in close proximity to a highly homologous
inactive pseudogene CYP21P (CYP21A1P, CYP21A)1*.
Recombinations and conversions between CYP21P
and CYP21 result in the generation of dysfunctional
CYP21 alleles1·9. Approximately 90% of CYP2J
mutations are a result of CYP21P-denved con-
versions and recombinations1'2. In the case of
compound heterozygous mutations the milder of
the two mutated alleles determines the CAH
phenotype.
CYP21 genotyping can be useful in the diag-
nosis of CAH and can also predict the phenotype in
80-90% of cases10"13. Given the imprecision
inherent in the clinical classification of CAH this
degree of genotype-phenotype correlation could be
expected. There is a good genotype-phenotype
correlation for very severe and very mild CYP21
mutations, whereas the correlation between geno-
type and phenotype is less precise when the
underlying mutation results in an intermediate
impairment in enzyme activity10'12"14.
There are a number of common haplotypes of
the CYP locus15"20. The most common CYP haplo-
type is a single functional CYP21 gene with one
CYP21P gene upstream, haplotype A in Koppens et
α/.20. A large scale deletion event can lead to
CYP21 gene deletion, haplotype E. or the formation
of a dysfunctional CYP21P/CYP21 hybrid gene,
haplotype E-Hyb20. The most common reported
haplotypes in CAH are E, E-Hyb and A (with
CYP21 mutation). However, many other haplotypes
have been reported in CAH and in normal
individuals with varying numbers of CYP21,
CYP21P and CYP21P/CYP21 hybrid genes (haplo-
types B, C, D, F, G, II and I20).
A common problem with any CYP21 geno-
typing protocol is the high homology between
CYP21 and the pseudogene CYP21P. Some
protocols achieve specificity for CYP2I via puri-
fication of a 3.5 kb Taq-1 digested genomic DNA
fragment containing CYP21 but not CYP21P13'21.
This purified digestion product is then used for
polymerase chain reaction (PCR) amplification
and/or other methods (e.g. restriction fragment
length polymorphism [RFLP], single strand confor-
mational polymorphism [SSCP], denaturing gra-
dient gel electrophoresis [DGGEJ) to screen for
mutations. Due to genetic variation, however, the
3.5 kb Taq-1 fragment does not always contain the
CYP21 gene15.
Other assays involve direct PCR amplification
from genomic DNA using allele specific PCR. A
separate PCR reaction is performed for each of
the common mutations screened14'22"25. These pro-
cedures are cumbersome due to the number of
reactions required. Other assays involve direct
amplification of CYP21 from genomic DNA using
specific primers, followed by a second round of
PCR to screen for common mutations26"30. Any
assay involving more than one round of PCR is
subject to problems with specificity and sensitivity.
Other assays screen for mutations via migration pat-
terns of PCR products on gels (SSCP, DGGE)21·30'31,
but can be associated with low sensitivity. Some
studies describe first-round screening for common
mutations using the methodologies described
above, and if two mutations are not detected this is
followed by DNA sequencing to detect rare or
novel mutations12·13'21·25'26·31.
This paper describes a thorough genotyping
methodology in which all mutations, common and
rare, are detected by complete gene sequencing of
CT.P27-specific PCR products amplified directly
from genomic DNA. We believe that our assay is
simpler and more accurate than the other protocols
discussed above. We performed genotyping ana-
lysis of the CYP21 locus on a series of Australasian
patients with CAH and family members as part of
our diagnostic genotyping service at the Mater
Children's Hospital. Phenotype-genotype corre-
lations, family studies, and analysis of novel
mutations and rearrangements are described.
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PATIENTS AND METHODS
Patients
Twenty-six unrelated probands with CAH and
seven affected family members were genotyped.
For clinical details see Tables 1 and 2. Detailed
clinical information is only provided for those
patients with unusual genotypes or family pedigrees
(Table 1). The CAH phenotype was determined by
clinicians according to defined clinical criteria2.
Four CAH subtypes were used in order of in-
creasing severity: carrier, NC, SV and SW (Tables
1, 2). The clinical phenotype of some patients can
best be described as intermediate between cate-
gories, e.g. NC-SV for patient PI.
CYP21 genotyping
DNA purification
Genomic DNA (gDNA) was extracted from
peripheral leukocytes32. For prenatal testing, gDNA
was extracted from chorionic villus samples using
Wizard Genomic Purification Kit (CAT#A1120,
Promega, Sydney, Australia).
Gene copy assay
The gene copy assay was used to determine the
copy number of CYP21 and CYP21P genes. PCR
with non-gene specific primers was used to amplify
a small region in exon 3 which contains an 8 base-
pair (bp) deletion in CYP21P but not in CYP21
(Fig. 1, 'Ex3-A8bp' and 'Ex3-8bp intact'). The size
and relative intensity of CYP21, CYP21P and
control gene -globin PCR products was deter-
mined by GeneMapper analysis (Fig. 1).
For the gene copy assay, gDNA was PCR
amplified in 50 μΐ containing 0.5 μΜ each of
primers 12/E3-665S and E3-824AS (see below for
details of oligonucleotides), 0.2 μΜ each of β-
globinS and -globinAS, 0.2 μΜ dNTPs, 1.5 mM
Mg**, l U Amplitaq Gold DNA polymerase and
buffer (CAT# N8080161, Perkin Elmer, Sydney,
Australia). PCR cycling conditions were: 95°C 3';
35 χ 95°C 30":58°C 30":72°C 30"; 72°C 3'. PCR
products were visualised using agarose gel electro-
phoresis, purified using High Pure PCR product
purification kit (CAT# 1732668, Roche, Mannheim,
Germany) and subjected to GeneMapper analysis
on a ABI 3130x1 capillary DNA Sequencer
(Griffith University Sequencing Facility, Nathan,
QLD, Australia).
PCR sequencing O/CYP21
Mutations in CYP21 were detected by PCR-
amplification of the entire CYP21 gene using
CYP21 specific primers followed by sequencing
using nested sequencing primers. Two PCR
products were produced. The first PCR product
spans the first six exons and proximal promoter
region of the CYP21 gene. The second PCR
product covers the 5'-UTR, all ten coding exons,
introns and partial 3'-UTR ofCYP21 (Fig. 1).
For the exon 1-6 PCR (1,574-bp product),
gDNA was PCR amplified in 100 μΐ containing 1
μΜ each of 5'-ml74S and E6-1400AS, 0.2 μΜ
dNTPs, 1.5 mM Mg++, 2 U TaqFl DNA poly-
merase and buffer (CAT#TAQ-1, Fisher Biotec,
Sydney, Australia). PCR cycling conditions were:
95°C 3'; 35 χ 95°C l':65°C 2':72°C 3'; 72°C 3'. For
the exon 1-10 PCR (2,939-bp product), gDNA was
PCR amplified in 100 μΐ containing 1 μΜ each 5'-
m!26S and 3'-2813AS, 0.2 μΜ dNTPs, 1.25 mM
Mg**, 3.75 U Expand Hi-Fidelity Taq polymerase
with buffer (CAT# 04738250001. 4738250, Roche,
Mannheim, Germany). PCR cycling conditions
were: 95°C 1'; 14 χ 95°C l':65°C l':72°C 6'; 20 χ
95°C l':65°C l':72°C 6'+2" each cycle; 1 χ 95°C
r:53°Cl':720C151;720C31.
The PCR products were visualised on agarose
gel, purified and sequenced using a variety of
nested sequencing primers. Sequencing reactions
utilised Big-Dye-Terminator-Cycle-Sequencing-
Ready-Reaction (CAT#4303149, Applied Biosystems,
Scoresby, Australia). Sequencing analysis was
performed at Griffith University Sequencing
Facility. All sequences were compared to consensus
sequences for CYP21 (Genbank RefSeq NC-
000006).
Parents and family members were genotyped for
the specific mutations detected in probands using
PCR sequencing and gene copy assays.
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Nomenclature for CYP21 mutations
All amino acids are referred to using the single
letter code. Mutations are listed as amino acid
substitutions in 21 -hydroxylase protein, except
where otherwise indicated. Amino acid numbering
is as in the Human Gene Mutations Database
(www.hgmd.cf.ac.uk) and wAvw.cypalleles.ki.se/
cyp21; numbering starts from A in the initiation
codon; the polymorphic insertion of amino acid
L10 has been omitted. Nucleotides associated with
amino acid substitutions are numbered relative to
cDNA sequence Genbank RefSeq NM000500
where nucleotide 1 is the first A of the ATG start
codon. All other nucleotides are numbered relative
to gDNA sequence Genbank RefSeq NC000006,
where the first A of the ATG start codon
corresponds to nucleotide number 1.
Details of oligonucleotides
ß-Globin primers: ß-GlobinS 5'ACACAACTGTG
TTCACTAGC3' and ß-GlobinAS 5'CAACT
TC ATCCACGTTCACC3'.
CYP2J primers: Primer labels, e.g. E6-1400AS;
exon or intron number - position of 5'-base of
primer-antisense (AS) or sense (S). Primers E6-
1400AS and 5'-ml26S are specific for the
CYP21 gene. All other primer sequences are
identical in both CYP21 and CYP21P. Position
of the 5'-base of the primer is numbered relative
to Genbank RefSeq NC000006. PCR primers
were 12/E3-665S 5'CCTGCAGACAAGCTGGT
GTC3'. E3-824AS 5'CACAGAACTCCTGGGTC
AGCTGC3', 5'-ml74S 5'CAAGGCCAATGA
GACTGGTGT3', E6-1400AS 5'AGCTGCATC
TCCACGATGTGA3', -5'-ml26S 5'CGGGTC
GGTGGGAGGGTA3' and 3'-2813AS 5'AGC
GATCTCGCAGCACTGTGT3'.
Additional sequencing primers were:
5 '-m 152S 5 'ATTCCAGAAAAGGGCCACTC3'.
E1-200AS 5 TGC AGCCC AAGGTGG AGC3'
E2/I2-371S 5'AGACCTGAGCCACTTACCTG3',
E3-826AS 5 'CTCACAGAACTCCTGGGTCA3',
E4-1009S 5 'TACCTCACCTTCGGAGACAA3'.
15-1313AS 5 'CATGAGAATGCAGCTGTGG3'.
16-1449S 5 'AC AGCCAGTGATGCTACC3'.
E7-1619AS 5'CCATCATGTCCCTCCACTG3'.
17-1976AS 5' ATGATCGGGTGG AGTCCT3'.
18-2191 AS 5'CTCACTCATCCCCAACCCT3',
18-2180S 5OGGATGAGTGAGGAAAG3',
3 '-2776AS 5 'AGGGGTTCGTACGGGAGCAA3'.
CYP haplotypes and hybrid genes
CYP2JP/CYP2J hybrid genes can have break-
points anywhere from just downstream of Ex3-
A8bp to exon 8 (exon 3 hybrid is the most
common). CYP21P/CYP21 hybrid genes give an
identical result in the gene copy assay as intact
CYP21P genes. CYP21P/CYP21 hybrid genes with
a breakpoint 5' of primer E6-1400AS will amplify
in the exon 1-6 PCR assay but not in the longer
exon 1-10 PCR assay. CYP2IP/CYP2I hybrid
genes with a breakpoint 3' of primer E6-1400AS
will not be amplified at all. For simplicity in
presentation of data, CYP21 deletion and CYP21P/
CYP2J hybrid alleles have been grouped together
and listed simply as 'Deln/Hyb'.
It is possible to use gene copy results in
combination with PCR sequencing data from
probands and family members in order to estimate
which of the known CYP haplotypes reported in the
literature may be present (possible haplotypes have
been listed using the nomenclature of Koppens et
/.20).
Ethics
All patients were genotyped by the Mater
Molecular Genetics Laboratory, Mater Pathology,
Mater Misericordia I lospital, South Brisbane, QLD.
The Mater Molecular Genetics Laboratory is
accredited by the National Australia testing
authority (NATA). Patient genotyping by the Mater
Molecular Genetics Laboratory has been approved
by the Mater Health Services Human Research
Ethics Committee (MHSHREC).
RESULTS
Twenty-six probands (14 female, 12 male) with
CAH as well as seven affected family members
were referred for genotyping. All probands were
from Australia or New Zealand. Two of the 26
probands (P6 and P7) were from families of Middle
Eastern origin with consanguineous marriages.
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TABLE 1
Clinical details of probands and affected family members
ID# Presentation and Notes Meds*
Probands:
PI Unsure if NC- or SV-CAH. Diagnosed at birth, known family history (older sister diagnosed with SV-CAH at age 2 HC,
yr), I7OI1P 125 mM. Adult height 162cm, no incidence SW crisis. At age 29 yr compliant on treatment and CAH is prednisone
well controlled.
P2 SV-CAH. Diagnosed at age 2.5 yr after presentation of sister at birth with SV-CAH. Rapid growth, large phallus, HC
17OHP 64 mM. At age 8 yr progressing well, growth p50-75.
P3 SW-CAH. Presented at age 10 days with vomiting and hyponatremia (17OHP 1,747 mM, Na* 1 IS mM). No family FC, HC
history of CAH. At age 2.5 yr is progressing well. Growth p50-75, Na*/l7OHP normal. Family pedigree in Figure 2.
P4 SW-CAH. Virilisation noted at birth. Presented age 14 days with SW crisis (Na* 130 mM, K* 5.7 mM. 17OHP 229 FC. HC
mM, cortisol 203 mM). Resuscitated with IV fluids. Urethrogram showed vaginal sinus only, no vaginal vault. From
age 0-3 yr history of high I7OHP, SW crises and gastroesophageal reflux. At age 3 yr growth is satisfactory and
clitoral enlargement less obvious.
P6 NC-CAH. P6 and his sister both have NC-CAH. Four other siblings of P6 are not affected. P6 and his wife are first
cousins and are also related through a second line of descent. Consanguineous family, of Middle Eastern origin.
P7 SW-CAH. Diagnosed at age 3 mo. At age 5 yr bone age is 12 yr and 17OHP/androgen levels are high. No family FC, HC
history of CAH. Parents normal stature. Older sister had normal genitalia, died at age 5 mo with pneumonia.
Consanguineous family, of Middle Eastern origin
P13 SW-CAH. Presented age 16 days SW crisis, hyperkalemia, hyponatremia, high 17OHP/PRA, mild hyperpigmenta- FC. HC,
tion of genital skin. At age 5 yr is progressing well with normal growth/bone age. Family pedigree in Figure 3. Na*
P14 SW-CAH. Also diagnosed with renal dysplasia. At age 8 yr is progressing well with normal bone age/stature, no FC. HC
virilisation. Family pedigree in Figure 3. Genotrop
PIS SW-CAH. Died of SIDS at age 5 mo, no history of vomiting, early sexual development or illness. Autopsy showed
bilateral adrenal hyperplasia and biochemistry indicative of SW-CAH. A male sibling bom after PI J was diagnosed
with CAH prenatally using HLA typing. Family pedigree in Figure 3.
Affected family members:
A4 A4 diagnosed at birth with septo-optic dysplasia (SOD), panhypopituitarism, hypothyroidism, pituitary gland FC. HC.
dysfunction. A4 was born 2 years before P4. When P4 presented with CAH diagnosis of A4 was amended to include growth
SW-CAH. From age 0-4 yr history of hypoglycemia, hyponatremia. infections, irregular sleep, poor growth (age 4 yr hormone,
height/weight <p5, bone age 2.75 yr. At age 5 yr progressing well; hypoglycemia less severe, good hearing, recurrent melalonin.
middle ear infections. Family history of type 2 diabetes mellitus but no history of CAH. SOD or consanguinity. thyroxine
A13 During a clinic visit for PI 3 the mother noted that older sister A13 at age 5 yr had clitoromegaly. body odour, acne. HC
Examination showed height p75. weight p90, bone age 6.5 yr(!7OHP 120 mM. renin 38 mU/l, Na* 138 mM. K* 4.7
mM). AI3 diagnosed with NC-CAH. At age 6.5 yr progressing well, bone age 8 yr. Pedigree in Figure 3. Father had
early onset puberty, cessation of growth at age 11-12 yr. adult height of 173 cm. Two of the father's siblings have
NC-CAH features. No family history of consanguinity or miscarriages.
A19 SW-CAH. Diagnosed in utero. Chorionic villus sample from mother genotyped at 10 weeks gestation.
* Meds = medications: FC = fludrocortisone: HC = hydrocortisone: Genotrop = Genotropin.
CAH = congenital adrenal hyperplasia: NC = non-classic: SV = simple virilising: SW = salt-wasting.
p = percentile
VOLUME 22. NO. 2.2009
Brought to you by | University of Queensland - UQ Library
Authenticated
Download Date | 10/27/15 5:12 AM
132 Y.W.A.JESKEETAL.
TABLE 2
CYP21 genotyping in probands and affected family members
ID# Sex CYP2I genotype
Allele 1 ' Allele 2
Expected phenotypes
Phen.
Allele 1
Phen.
Allele 2
Observed
phenoype
Gene copy
C21 C21P
Probands:
PI
P2
P3
P4
P5l
P6H
P7"
P8
P9"
P10F
Pll
P12
PI3
P14
P15
P16
P17
P18
P19
P20
P21
P22
P23F
P24
P25
P26
Affected
A4
AS1'
A13
F14
A17
A19
A20
M
M
M
F
F
M
M
F
F
F
F
F
M
M
M
M
M
F
F
F
F
M
F
F
M
F
family
M
M
F
M
F
-
F
12 G Splice
I172NW
3 "Hybrid" M»
II72N
V28IL
R339H.P453S (M)
Q318Xf.W;
P453S.Int2 (M)
12 G Splice (M)
Deln/lhb
12 G Splice (\l)
P30L
12 G Sphce (M)
Deln/Hyb IM)
Deln/lhb M/;)
II72Ntfi>
I172N
12 G Splice (M)
Deln/Hyb (M)
II72Nr.U;
II72NC.U;
Deln.Hybf.WJ
I172N
12 G Splice
P30L
Prom. Cluster
members:-
II72N
D106NN
12 G Sphce (M)
V281I,
I172N
Deln/IhbC.U;
\\12\IMi
\VT
Ι1365ΥΝ^
Dcln/H)b (P)
Large ΔΝ
Ex3 A8bp
R339H.P453S (P)
Q318XtfV
Q318Xff>;
Deln/lhb tfV
12 G Sphce
II72Ntf>;
12 G Sphce
Deln/Hyb (P)
Q3I8XC/1;
Π72Ν<7>;
12 G Splice (P)
Ι172ΝΟΓΔ??
Deln/Hyb (P)
Deln/Hyb (P)
Dein 'Hyb (P)
Deln/H>b (P)
12 G Sphce (P)
12 G Splice
12 G Sphce /Δ?
II72N
II72N
Large Δ
WT
P30L (P)
Q3I8X
ΙΙ72ΝΟΓΔ??
Deln'Ihbr/V
Deln/lhhf/';
SW
SV
SW
SV
NC
NC
SW
SW
SW
SW
SW
NC
SW
SW
SW
SV
SV
SW
SW
SV
SV
SW
SV
SW
NC
Norm/NC
SV
9
SW
NC
SV
SW
SV
Norm
7
SW
SW
SW
NC
SW
SW
SW
SW
SV
SW
SW
SW
SV
SW
SV/SW
SW
SW
SW
SW
SW
SW
SW
SV
SV
SW
Norm
NC
SW
SV/SW
SW
SW
NC/SV
SV
SW
SW
NC
NC
SW
SW
SW
SW
SV
NC
SW
SW
SW
SV
SV
SW
SW
SV
SW
SW
SW
SW
SV
NC
SW
Norm
NC
NC
SV
SW
SV
2
2
1
1
1
2
2
2
1
1
2
2
1
1
1
2
-
1
0
1
-
1
2
-
2
2
1
2
2
2
-
0
1
2
2
2
1
4
2
2
2
2
3
3
3
3
2
3
2
-
2
2
2
-
2
2
-
2
2
1
2
2
3
-
2
2
Relation
Brother
Partner
Sister
Father
Sister
Sibling
T'vin
Phen. Allele 1, Phen. Allele 2 ~ phenol)pc associated with mutation on each allele, as listed in www.cypalleles.ki.se (note that
the expected phenotype is the milder of the two alleles).
Observed phenotype based on clinical information; Norm = normal; NC = non-classic: SV = simple virilising: SW = salt-wasting
Gene copy: C2\ = copies of CYP21 gene (Ex3 8bp deletion absent); C2IP = copies of CYP21P gene (Ex3 8bp deletion
present). Gene copy assay for P17, A17. P21 and P24 technically unsatisfactory, re-collection declined.
(M) = maternal allele, (P) = paternal allele (if known, not all parents were genotyped).
N
 Novel mutation or interesting mutation.
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Table 2 continued
v
 P5 was genotyped with her unaffected partner A5 prior to family planning (family pedigree in Figure 2). A5 is carrying a
novel mutation. The novel mutation may be deleterious, thus A5 is included in the table even though unaffected.
H
 Family genotype/gene copy results are consistent with unusual haplotypes on the non-disease allele of unaffected subjects in
families 6,7 and 9 (data not shown).
F
 P10 and P23 have each been listed as index case probands even though they are distantly related.
CYP21 genotype:
Deln/Hyb = entire deletion ofCYP21 gene, or CYP21P/CYP2I hybrid gene.
3' Hybrid = CYP2I/CYP21P hybrid gene.
Large Δ = novel large scale deletion encompassing CYP21P and CYP21 genes.
Ex3 Δ 8bp = 8bp deletion in exon 3 (nucleotides 711-718).
12 G Splice = intron 2 IVS-13A/OG mutation (nucleotide 659).
R339H.P453S = double R339H and P453S mutations in CYP21 gene.
P453S.Int2 = double P453S and 12 G Splice mutations in CYP21 gene.
Prom. Cluster = promoter cluster, nucleotides minus -126C-T, -l 13G-A, -l 10T-C, -103 A-G.
WT = wildtype CYP2I llele, i.e. no mutation detected.
Fourteen of the 15 probands (9 females, 5
males) with SW CAH presented at <3 months of
age with virilisation and/or SW crises. One boy
(PI5) died at age 5 months and was diagnosed with
SW CAH on autopsy. Seven probands (2 female, 5
male) presented with SV CAH during childhood
while four probands had NC CAH (3 female, 1
male). See Tables 1 and 2 for more clinical details.
The genotyping results for the probands and
affected family members are presented in Table 2
(refer to www.cypalleles.ki.se/cyp21 and/or www.
hgmd.cf.ac.uk for details on CYP21 mutations
listed in Table 2). The overall distribution of
CYP21 mutations in the Australasian CAH cohort
is comparable to other studies (Table 3). The most
common deleterious CYP21 alleles were: 1) large
scale rearrangements (CYP21 deletion or hybrid
genes) (33% of alleles); 2) 12 G splice (34%); and
3) I172N (11%). At least one of these three alleles
was present in 85% of cases. The deletion/hybrid
and 12 G splice mutations were associated with SW
CAH. However, when I172N was the least severe
mutation it was associated with a simple virilising
phenotype in 55% of compound heterozygotes and
a salt-wasting phenotype in 45% of compound
heterozygotes.
Proband PI was unique in having only one
mutation of the CYP21 gene detected. P4, A4 and
A5 had novel mutations. P2 and P3 had rare
mutations that have been previously reported in
CAH but which are discussed in detail herein as
available information is limited.
Probands P6 to PI2 and/or family members had
unusual gene copy results suggesting the presence
of unusual haplotypes20. The families of P13, P14
and P15 were each found to have three deleterious
CYP21 alleles, i.e. mixed pedigrees.
Proband / Family 1
Proband PI has the intron 2 G mutation on one
allele and no detectable mutation on the other
allele, although CYP21 polymorphisms were
heterozygous. Gene copy results indicate the
presence of two CYP21 genes.
Proband / Family 2
Proband P2 has the I172N mutation on one
allele and an unusual amino acid substitution
H365Y on the other allele. H365Y is a result of a
nucleotide substitution in exon 8, n!096 CAC to
TAG.
Proband / Family 3
P3 has the Deln/Hyb mutation on one allele and
an unusual hybrid gene, 3' Hybrid, on the other
allele consisting ofCYP2J sequences at the 5'-end
and CYP21P sequences at the 3'-end. Putative
haplotypes for Family 3 and a possible mechanism
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*CYP21
specific
primer
l·-
160bp CYP21
•152 bp CYP21P
\ I I
•152 bp CYP21P/CYP21 Hybrid(Ex3 breakpoint)
3 CYP2IP : 1 CYP2I
A /
2CYP2IP OCYP2I
:· ι
2 CYP2IP : 1 CYP21
A /
2 CYP2IP : 2 CTP2/
i /
.-. A/
;. ;./
i A,
?. i/
Size Marker 100 bp 1 139 15C
B-Globin CYP2
H O b p 1521
J
J
.•i
160
//> C
ρ ι
YP2I
50 bp
Fig. 1: Upper panel: PCR assay of CYP21 and CYP21P. CYP2I and CYP21P genes are depicted, as is the common exon 3
hybrid aene. Shaded boxes represent CYP21P gene sequences, and the ten exons are depicted as grey boxes. Large arrows
indicate5 PCR primers used for PCR sequencing and gene copy assays. Small arrows indicate sequencing primers. The two
large CYP21 PCR products used for CYP21 ?ene sequencing are shown at the top. The three short gene copy PCR
products are shown below each gene. The presence of the exon 3 8-base-pair (bp) deletion in CYP21P and the hybrid gene
results in a product of smaller"size than the CYP21 PCR product. Lower panel: Gene copy assay. The short PCR
products spanning the exon 3 8-bp deletion (152 bp for CYP2IP and 160 bp for CYP2I) are analysed quantitatively using
capillary electrophoresis followed by GeneMapper analysis. Peak heights are compared to a -globin gene PCR product to
determine CYP copy numbers (assuming two -globin gene copies).
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TABLE 3
Aliellic distribution of mutations in CAM
Study
# Alleles
Year
Ref.#
Mutation
Dein/hybrid
12 G splice
I172N
\'28IL
P30L
Ex38bp
Q318X
R356W
Ex6 cluster
P453S
PC Main *
Other **
Total
Number of
mutations
screened
% of total alleles
A
us
tra
la
sia
134
2007
33.5
34.4
11.3
3.7
22
1.5
3.0
0
0
0
3.7
6.7.
all
it
"c .5
284
1999
22
45
30.3
7
0
0
nt
0
9.8
nt
0
0
7.9
17
G
er
m
an
y
310
2000
13
27.4
30.3
19.7
2.9
2.6
1.6
4.8
4.5
1
0.3
0.3
4.6
all
N
et
he
rla
nd
s
370
2003
26
31.9
28.1
12.4
2.2
0.3
4.3
3.5
84
3
0.5
2.2
3.2
all
Sw
ed
en
400
1998
25
32.2
26.6
19.8
5.7
1.6
1.1
2.4
3
1.1
0.5
0.5
5.5
all
D
en
m
ar
k
136
1999
21
36.8
32.4
9.6
2.2
2.2
0.0
7.4
0.7
0.7
0.0
2.9
5.1
all
" X
=5 g· ,.
•ο Ε .£·
696ε
2005
31
30.6
31.2
145
3.4
3.7
1.0
2.6
2.4
0.3
0.7
7.2
2.4
all
146
1996
27
20
19.9
6.2
11
2.7
1.4
8.2
0
0
nt
0
30.6
100
9
4li
u
222
2001
23
13.5
29.3
13.5
10.8
11.3
2.3
8.6
0.5
00
3.6
0.5
6.3
12
•a
c
.Ξ
c
£
156
1997
12
46.8
96
• 31.4
26
0.0
0.0
1.3
0.0
00
00
3.2
5.1
all
<
394
1995
14
25.6
29.9
96
9.4
2.5
2.8
4.1
38
nt
nt
8 1
4.1
10
c
ce
c.
68
1999
29
11.8
265
11.8
00
1.5
00
88
17.6
1.5
nt '
2.9
17.6
10
R
JZ
W
130
1998
30
108
41.5
223
00
00
1.5
08
15.4
0.0
00 .
23
5.4
I I
'N
ce
03
228
1998
24
10.9
18.5
13.2
16.6
1.7
09
49
72
04
1.3
4.6
19.9
16
Compiled results from extensive literature search of worldwide cohort studies, including analysis of methods used in each
study.
The % allele frequency for each study was calculated from raw data cited in the literature.
The table includes data on a total of 67 unrelated Australasian CAM probands (patients from Australia and New Zealand; 134
alleles). Only 26 of these 67 probands are presented in detail in this paper (Table 2). Forty-one of the 67 CAH probands were
genotyped in our laboratory from de-identified blood samples in the process of optimising the CYP21 assay and generating
positive control samples for quality control; no clinical data on these 41 subjects are available.
* PG Mutn = other pseudogene mutations tested for. Note that not all pseudogene mutations were tested for in each study
(includes combinations of pseudogene mutations, i.e. those tested for).
** Other - includes: 1. rare non-pseudogene mutations; 2. novel mutations; 3. no mutation; 4. 'undefined genotype', e.g. other
known mutations not tested for.
nt = not tested for.
E
 Middle Europe: MESPE database subjects = Austrian, Czech, Hungarian, Slovakian, Slovenian (individual populations had
similar allele frequencies).
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for generation of the 3'-Hybrid are depicted in
Figure 2. A crossover between haplotypes F and D
may have resulted in generation of the 3' Hybrid
allele. The breakpoint of the 3' Hybrid gene is
somewhere between the exon 3 8-bp deletion and
I172N mutations. It is impossible to determine the
precise position of the breakpoint due to the high
sequence identity between CYP21 and CYP21P.
Chi-like sequences may be recognition sites for the
recombinase complex responsible for gene recom-
bination33"35. There is a chi-like sequence GCT
GGGC at the beginning of intron 3 suggesting that
this may be the 3' Hybrid breakpoint.
Proband / Family 4
P4 and her affected brother A4 both have the
I172N mutation on one allele and a large novel
deletion on the other allele. The extent of the large
deletion was not determined, but includes both
CYP21 and CYP21P.
Proband / Family 5
P5 has NC CAH and was referred for pre-
conception genotyping with her unaffected partner
A5 (Fig. 2). The CYP21 mutations in P5 are
previously described and consistent with her pheno-
type. The partner A5 was found to carry a novel
amino acid substitution D106N on one allele.
D106N is a result of a nucleotide substitution in
exon 3, n319 GAC to AAC. CYP genotypes and
haplotypes for Family 5 are depicted in Figure 2.
Probands / Families 6 to 12
Genotyping and gene copy results for P6, P7,
P8, P9, P10, Pl l , P12 and available family mem-
bers indicate the presence of unusual haplotypes B
(CYP21P deletion), C (one copy CYP21, two
copies CYP21P) and D (CYP21 deletion, two
copies CYP21P).
Proband / Family 13
Three different deleterious CYP21 alleles,
Deln/Hyb, intron 2 G and P30L were found in
Family 13, consistent with the observed phenotypes
of both SW and NC CAH (Fig. 3). The Deln/Hyb
allele in PI3 has an extra copy of CYP21P
(haplotype D) and the non-disease allele in the
mother has a CYP21P deletion (haplotype B).
Proband / Family 14
Three deleterious CYP21 alleles were found in
Family 14, consistent with the S W and NC CAH
phenotypes observed (Fig. 3). The V281L allele
found in patient F14 has a CYP21P duplication
(haplotype C).
Proband / Family 15
PI5 has the I172N mutation on one allele and
the Deln/Hyb mutation on the other allele. The
index case PI5 and an affected sibling have been
previously described in a case report36. Additional
genotyping data on family members is reported
herein. The maternal aunt is a carrier of the
Deln/Hyb allele. Her husband was also genotyped
and found to carry the mutation P453S (Fig. 3). The
Deln/Hyb allele found in PI5 has an extra copy of
CYP21P (haplotype D).
DISCUSSION
Unlike many CYP21 genotyping protocols the
methodology used in this study involves sequen-
cing of the entire CYP21 gene including exons,
splice sites and the proximal promoter, therefore
allowing for the detection of less common muta-
tions. Three of the 26 probands had novel or rare
mutations which would have remained undetected
if only common mutations had been screened for.
The phenotypes predicted from the genotyping
results generally agree with the clinical phenotype
(76% of cases). However, we found the I172N
mutation was associated with either a SV or SW
phenotype, although generally reported in the
literature as being associated with SV CAH (Table
2). The high sensitivity in detecting mutations and
the good genotype/phenotype correlation illustrates
the value of CYP21 genotyping by sequencing.
As mentioned, five patients (P4, A4, P15, P21
and P23) have S W CAH although the milder allele
I172N predicts a SV phenotype. Other studies have
also indicated phenotypic variability for the I172N
mutation10·12·13'26'31. It is possible that the genetic
background may play a role in modulating the
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Fig. 2: CYP21 genotypes and haplotypes. Upper panel: Pedigree and genotyping results for Family 3. The gene copy results
are consistent with known haplotypes E, F-Hyb and C. A possible mechanism for the generation of the unusual '3'Hybrid'
allele is indicated in the lower part of the figure. Lower panel: Pedigree, genotypes and possible haplotypes (based on
gene copy results) for Family 5.
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Fig. 3: Families with three CYP21 mutations.
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effect of the I172N mutation on the enzyme activity
of 21-hydroxylase. Two other probands have a
clinical phenotype more severe than predicted by
genotype: P25 has SV CAH although the milder
allele P30L predicts NC, and PI has NC-SV CAH
but was found to have only one allele mutated
(intron 2 G). Allele drop-out is not the cause of
detection of only one mutation in PI as hetero-
zygosity was observed for CYP21 polymorphisms.
The non-concordance of genotype and phenotype in
PI and P25 could be due to genetic background
and/or undetected CYP21 promoter or regulatory
mutations. An alternative explanation for non-
concordance of phenotype with genotype is clinical
misclassification of the phenotype, with a tendency
to Over-call' the phenotype.
CYP21 genotyping data from various worldwide
cohort studies is provided in Table 3. Data from a
large number of countries are included: UK22,
Germany13, The Netherlands26, Sweden25, Denmark21,
Middle Europe31, Italy27, Greece23, Finland12,
USA14, Japan*, China30 and Brazil24. The distribu-
tion of CYP21 mutations in the Australasian CAH
cohort is similar to that in other populations. As
would be expected, studies that screened for only
the common CYP21 mutations often report a higher
incidence of 'undefined' (novel/rare) mutations, for
example Italy (30.6%) and Japan (17.6%). It is of
note that the incidence of rare/novel mutations in
our Australasian cohort (6.7%) is slightly higher
than in the other studies that screened for all
CYP21 mutations, for example Germany (4.6%),
The Netherlands (3.2%), Sweden (5.5%), Denmark
(5.1%) and Finland (5.1%).
In addition to CYP21 gene sequencing for
detection of mutations, our genotyping protocol
includes a quantitative CYP21 and CYP21P gene
copy assay. The gene copy assay described herein
does not provide a detailed map of the CYP region
and does not precisely determine haplotype. Rather,
this assay counts the number of copies of Ex3-8bp
intact and Ex3-A8bp giving an indication of the
number of copies ofCYP21 and CYP21P (Fig. 1).
The quantification of CYP copy number relies on
the assumption that each individual has two intact
copes of the ß-globin gene. This assumption is not
always correct as gene copy number in the human
genome is variable 7.
The PCR sequencing data corroborate the gene
copy results. CYP21 contains many non-functional
polymorphisms. The presence or absence of hetero-
zygosity for these indicates whether one or two
copies of CYP21 are present. Care must be taken in
the case of consanguineous families; if the proband
has inherited two identical alleles all polymorph-
isms will be homozygous and only genotyping of
the parents can rule out hemizygosity.
The gene copy and PCR sequencing results from
probands and family members allow an estimation
of the possible haplotypes present. Future more
detailed haplotype analysis in CYP21 genotyping
will be important. Studies on genotype to pheno-
type correlations in other diseases have shown that
the haplotype may be more predictive than the
genotype alone37"3 , and this may also be the case
for CAH.
We describe several CAH families with mixed
pedigrees. One of these, Family 13, illustrates the
clinical benefit of CYP21 genotyping. Two CAH
phenotypes, NC and SW, occur in this family due
to the presence of three deleterious CYP21 alleles
(Fig. 3). The members of this family with NC CAH
(father, sister) were only detected as a consequence
of the presentation of the proband with SW CAH.
The father had early puberty and diminished adult
height which has been reported in NC CAH40"44.
The results for Family 13 suggest that NC CAH
may go undetected in the general population and
genotyping should help those patients who may
benefit from treatment. In addition, genotyping is
vital for family planning in any mixed pedigree
such as Family 13. Similarly, in Family 14 NC and
S W phenotypes arise from three deleterious CYP21
alleles (Fig. 3). The mother is a carrier for one of
the mutations but has a clinical profile indicative of
mild NC CAH. The mother was only genotyped for
the known mutations detected in the probands, and
it is possible the mother has another undetected
mutation leading to the mild NC phenotype.
The large scale deletion found in Family 4 has
not been reported to date and would be associated
with SW CAH. Whether the large scale deletion
includes other functional genes that contributed to
the hypopituitarism in A4 is unclear; however, P4
has an identical mutation without any evidence of
hypopituitarism.
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An unusual hybrid gene, 3' Hybrid, was de-
tected in Family 3 consisting of CYP21 sequences
at the 5'-end and CYP21P sequences at the 3'-end
(Fig. 3). A similar rearrangement has been
described in the literature45. The pseudogene
sequences at the 3'-end of the 3' Hybrid gene
include many deleterious mutations which render
the gene incapable of encoding active enzyme,
resulting in SW CAH.
One novel amino acid substitution D106N is
reported herein but it is unclear based on clinical
data whether this is associated with CAH. The rare
mutation H365Y has been reported previously in
CAH46 but no phenotypic information was
provided. Expression'studies on D106N and
H365Y have not been performed. Cotton et α/.47
outline criteria for predicting the effect of missense
mutations. If an amino acid change is non-
conservative (i.e. results in a change in chemical
properties of the side chain), if the residue is
conserved amongst various species, and if the
change is observed in affected but not in control
individuals, then it is likely to have an effect on
protein function. All criteria outlined by Cotton et
al.47 are fulfilled by the two missense mutations.
Robins et α/.48 have provided a structural model
of human 21-hydroxylase and analysed the effect of
many mutations associated with CAH including
H365Y. The active site of 21-hydroxylase includes
a cysteine binding pocket which binds covalently to
a haem molecule and the H365 residue is directly
involved in haem binding48'49. Robins et α/.48 predict
that H365 is most likely associated with SV or SW
CAH. Proband P2 in our patient cohort has SV
CAH and has the H365Y mutation on one allele
and I172N on the other allele. We have found that
I172N is associated with both SV and SW CAH
and it is thus impossible to predict based on the
phenotype of P2 which of H365Y or I172N is the
milder allele.
The novel substitution D106N was identified in
a normal individual A3 in the process of carrier
testing prior to family planning. The effect of con-
version of the small negatively charged aspartic
acid residue at position 106 to the small, polar,
uncharged asparagine residue is unknown. The
detection of a novel mutation in the partner of a
patient affected with CAH provides problems with
prenatal testing. If the novel mutation is detected in
the offspring in addition to a second mutation, then
it is impossible to predict CAH phenotype. The
difficulty in prediction of CAH phenotype for the
novel mutation D106N illustrates the importance of
in vitro expression analysis and modelling studies
as well as detailed descriptions of the phenotype
when novel mutations are reported.
The assay described in this paper is simple and
thorough, a fact illustrated by the detection of three
novel/rare mutations that would have been missed
using other protocols. CYP21 genotyping using
entire gene sequencing has a number of potential
benefits that have been illustrated in this paper.
Detection of novel mutations not only confirms the
genetic basis of CAH in individual probands but
also contributes to our understanding of genotype-
phenotype correlations when combined with func-
tional studies. Moreover, the application of accurate
and sensitive genotyping methods should improve
neonatal screening strategies and therefore facilitate
genetic counselling.
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